Brief communication: temporal trends of chronic diseases medications prescriptions among HIV-infected patients in Belgium: a 4-year population-based study using pharmacy claims data

Abstract The Objective of this study was to examine change over time of prevalence of chronic diseases medications (CDM) prescriptions among People living with HIV (PLWH) in Belgium, using Pharmanet database from 2018 to 2021. We identified 13,570, 14,175, 14,588 and 14,813 PLWH in 2018, 2019, 2020 and 2021, respectively. Prescriptions of cardiovascular diseases (CVD) medications (31.7–37.2%) and antidiabetics (7.4–9.0%), increased significantly (p for trend < 0.001 for all), while the prescription of neurological and mental disorders medications (18.0–19.3%) remained stable (p for trend =... Mehr ...

Verfasser: Dieudonné Ilboudo
Calypse Ngwasiri
Isabelle Savoye
Agnès Sommet
Dominique Van Beckhoven
Jean Cyr Yombi
Fati Kirakoya-Samadoulougou
Dokumenttyp: Artikel
Erscheinungsdatum: 2024
Reihe/Periodikum: AIDS Research and Therapy, Vol 21, Iss 1, Pp 1-6 (2024)
Verlag/Hrsg.: BMC
Schlagwörter: Chronic diseases medications / Prescriptions / Co-medications / People living with HIV / Belgium / Immunologic diseases. Allergy / RC581-607
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-28971239
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1186/s12981-024-00634-3

Abstract The Objective of this study was to examine change over time of prevalence of chronic diseases medications (CDM) prescriptions among People living with HIV (PLWH) in Belgium, using Pharmanet database from 2018 to 2021. We identified 13,570, 14,175, 14,588 and 14,813 PLWH in 2018, 2019, 2020 and 2021, respectively. Prescriptions of cardiovascular diseases (CVD) medications (31.7–37.2%) and antidiabetics (7.4–9.0%), increased significantly (p for trend < 0.001 for all), while the prescription of neurological and mental disorders medications (18.0–19.3%) remained stable (p for trend = 0.11) and the prescription of chronic respiratory diseases (CRD) medications decreased from 12.2 to 10.6% (p for trend < 0.001), between 2018 and 2021. It is imperative to ensure that these medications are used appropriately.